121 related articles for article (PubMed ID: 16983399)
1. No evidence for binding of clozapine, olanzapine and/or haloperidol to selected receptors involved in body weight regulation.
Theisen FM; Haberhausen M; Firnges MA; Gregory P; Reinders JH; Remschmidt H; Hebebrand J; Antel J
Pharmacogenomics J; 2007 Aug; 7(4):275-81. PubMed ID: 16983399
[TBL] [Abstract][Full Text] [Related]
2. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity.
Leysen JE; Janssen PM; Megens AA; Schotte A
J Clin Psychiatry; 1994 May; 55 Suppl():5-12. PubMed ID: 7520908
[TBL] [Abstract][Full Text] [Related]
3. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
Millan MJ; Gobert A; Newman-Tancredi A; Audinot V; Lejeune F; Rivet JM; Cussac D; Nicolas JP; Muller O; Lavielle G
J Pharmacol Exp Ther; 1998 Sep; 286(3):1341-55. PubMed ID: 9732398
[TBL] [Abstract][Full Text] [Related]
4. Preclinical pharmacology of FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: a potential novel antipsychotic with lower histamine H1 receptor affinity than olanzapine.
Rasmussen K; Benvenga MJ; Bymaster FP; Calligaro DO; Cohen IR; Falcone JF; Hemrick-Luecke SK; Martin FM; Moore NA; Nisenbaum LK; Schaus JM; Sundquist SJ; Tupper DE; Wiernicki TR; Nelson DL
J Pharmacol Exp Ther; 2005 Dec; 315(3):1265-77. PubMed ID: 16141369
[TBL] [Abstract][Full Text] [Related]
5. Radioreceptor binding profile of the atypical antipsychotic olanzapine.
Bymaster FP; Calligaro DO; Falcone JF; Marsh RD; Moore NA; Tye NC; Seeman P; Wong DT
Neuropsychopharmacology; 1996 Feb; 14(2):87-96. PubMed ID: 8822531
[TBL] [Abstract][Full Text] [Related]
6. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: II. Functional profile in comparison to clozapine and haloperidol.
Millan MJ; Schreiber R; Dekeyne A; Rivet JM; Bervoets K; Mavridis M; Sebban C; Maurel-Remy S; Newman-Tancredi A; Spedding M; Muller O; Lavielle G; Brocco M
J Pharmacol Exp Ther; 1998 Sep; 286(3):1356-73. PubMed ID: 9732399
[TBL] [Abstract][Full Text] [Related]
7. Amisulpride the 'atypical' atypical antipsychotic--comparison to haloperidol, risperidone and clozapine.
Natesan S; Reckless GE; Barlow KB; Nobrega JN; Kapur S
Schizophr Res; 2008 Oct; 105(1-3):224-35. PubMed ID: 18710798
[TBL] [Abstract][Full Text] [Related]
8. Clozapine and olanzapine, but not haloperidol, reverse cold-induced and lipopolysaccharide-induced cutaneous vasoconstriction.
Blessing WW
Psychopharmacology (Berl); 2004 Oct; 175(4):487-93. PubMed ID: 15083260
[TBL] [Abstract][Full Text] [Related]
9. Differential regulation of rat 5-HT2A and 5-HT2C receptors after chronic treatment with clozapine, chlorpromazine and three putative atypical antipsychotic drugs.
Kuoppamäki M; Pälvimäki EP; Hietala J; Syvälahti E
Neuropsychopharmacology; 1995 Oct; 13(2):139-50. PubMed ID: 8597525
[TBL] [Abstract][Full Text] [Related]
10. S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: II. Functional profile and a multiparametric comparison with haloperidol, clozapine, and 11 other antipsychotic agents.
Millan MJ; Brocco M; Rivet JM; Audinot V; Newman-Tancredi A; Maiofiss L; Queriaux S; Despaux N; Peglion JL; Dekeyne A
J Pharmacol Exp Ther; 2000 Jan; 292(1):54-66. PubMed ID: 10604931
[TBL] [Abstract][Full Text] [Related]
11. Dissociation of haloperidol, clozapine, and olanzapine effects on electrical activity of mesocortical dopamine neurons and dopamine release in the prefrontal cortex.
Gessa GL; Devoto P; Diana M; Flore G; Melis M; Pistis M
Neuropsychopharmacology; 2000 Jun; 22(6):642-9. PubMed ID: 10788763
[TBL] [Abstract][Full Text] [Related]
12. Novel antipsychotics: comparison of weight gain liabilities.
Wirshing DA; Wirshing WC; Kysar L; Berisford MA; Goldstein D; Pashdag J; Mintz J; Marder SR
J Clin Psychiatry; 1999 Jun; 60(6):358-63. PubMed ID: 10401912
[TBL] [Abstract][Full Text] [Related]
13. Effects of clozapine, olanzapine and haloperidol on ethanol-induced ascorbic acid release in mouse striatum.
Hou Y; Yang JY; Wu CF; Huang M
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jan; 29(1):83-9. PubMed ID: 15610949
[TBL] [Abstract][Full Text] [Related]
14. Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors.
Seeman P; Corbett R; Van Tol HH
Neuropsychopharmacology; 1997 Feb; 16(2):93-110; discussion 111-35. PubMed ID: 9015795
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties.
Oka M; Noda Y; Ochi Y; Furukawa K; Une T; Kurumiya S; Hino K; Karasawa T
J Pharmacol Exp Ther; 1993 Jan; 264(1):158-65. PubMed ID: 8093723
[TBL] [Abstract][Full Text] [Related]
16. Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro.
Bymaster FP; Nelson DL; DeLapp NW; Falcone JF; Eckols K; Truex LL; Foreman MM; Lucaites VL; Calligaro DO
Schizophr Res; 1999 May; 37(1):107-22. PubMed ID: 10227113
[TBL] [Abstract][Full Text] [Related]
17. Neurotensin-deficient mice have deficits in prepulse inhibition: restoration by clozapine but not haloperidol, olanzapine, or quetiapine.
Kinkead B; Dobner PR; Egnatashvili V; Murray T; Deitemeyer N; Nemeroff CB
J Pharmacol Exp Ther; 2005 Oct; 315(1):256-64. PubMed ID: 15987829
[TBL] [Abstract][Full Text] [Related]
18. Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents.
Albaugh VL; Henry CR; Bello NT; Hajnal A; Lynch SL; Halle B; Lynch CJ
Obesity (Silver Spring); 2006 Jan; 14(1):36-51. PubMed ID: 16493121
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of olanzapine, haloperidol and risperidone on calcitonin gene-related peptide in the rat brain.
Angelucci F; Gruber SH; Caltagirone C; Mathé AA
Neuropeptides; 2008; 42(5-6):535-41. PubMed ID: 18662828
[TBL] [Abstract][Full Text] [Related]
20. The effects of sub-chronic clozapine and haloperidol administration on isolation rearing induced changes in frontal cortical N-methyl-D-aspartate and D1 receptor binding in rats.
Toua C; Brand L; Möller M; Emsley RA; Harvey BH
Neuroscience; 2010 Jan; 165(2):492-9. PubMed ID: 19854242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
